Atrial Fibrillation Stocks List

Atrial Fibrillation Stocks Recent News

Date Stock Title
Nov 2 CVKD Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
Nov 1 MDT Medtronic (MDT) Outperforms Broader Market: What You Need to Know
Nov 1 MDT CMS grants Transitional Pass-Through Payment for Medtronic Symplicity Spyral™ renal denervation catheter
Nov 1 BMY Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade
Nov 1 BMY Bristol Myers posts long-term Phase 3 data for schizophrenia drug Cobenfy
Nov 1 BMY Company News for Nov 1, 2024
Nov 1 ITGR Integer Holdings Corporation Completes Divestiture of Non-Medical Business for $50 Million
Nov 1 ITGR Ultralife Corporation Completes Acquisition of Electrochem Solutions, Inc.
Nov 1 BMY Bristol-Myers Squibb Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Nov 1 BMY Bristol-Myers Squibb Co (BMY) Q3 2024 Earnings Call Highlights: Strong Growth and Strategic ...
Nov 1 BMY Q3 2024 Bristol-Myers Squibb Co Earnings Call
Nov 1 BMY Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY)
Oct 31 BMY Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
Oct 31 BMY A promising schizophrenia drug showed mixed results. What does that mean for patients?
Oct 31 BMY Bristol-Myers Squibb Company (BMY) Q3 2024 Earnings Call Transcript
Oct 31 BMY Bristol Myers Squibb (BMY) Q3 2024 Earnings Call Transcript
Oct 31 BMY Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS View
Oct 31 BMY Bristol Myers Stock Rises. The Drugmaker Hiked Guidance After Sales Beat.
Oct 31 BMY Bristol Myers Screams To A Year-High After Walloping Profit Expectations
Oct 31 BMY Bristol Myers Squibb stock rises, Merck moves lower. Here's why.
Atrial Fibrillation

Atrial fibrillation (AF or A-fib) is an abnormal heart rhythm characterized by rapid and irregular beating of the atria. Often it starts as brief periods of abnormal beating which become longer and possibly constant over time. Often episodes have no symptoms. Occasionally there may be heart palpitations, fainting, lightheadedness, shortness of breath, or chest pain. The disease is associated with an increased risk of heart failure, dementia, and stroke. It is a type of supraventricular tachycardia.High blood pressure and valvular heart disease are the most common alterable risk factors for AF. Other heart-related risk factors include heart failure, coronary artery disease, cardiomyopathy, and congenital heart disease. In the developing world valvular heart disease often occurs as a result of rheumatic fever. Lung-related risk factors include COPD, obesity, and sleep apnea. Other factors include excess alcohol intake, tobacco smoking, diabetes mellitus, and thyrotoxicosis. However, half of cases are not associated with any of these risks. A diagnosis is made by feeling the pulse and may be confirmed using an electrocardiogram (ECG). A typical ECG in AF shows no P waves and an irregular ventricular rate.AF is often treated with medications to slow the heart rate to a near normal range (known as rate control) or to convert the rhythm to normal sinus rhythm (known as rhythm control). Electrical cardioversion can also be used to convert AF to a normal sinus rhythm and is often used emergently if the person is unstable. Ablation may prevent recurrence in some people. For those at low risk of stroke, no specific treatment is typically required, though aspirin or an anti-clotting medication may occasionally be considered. For those at more than low risk, an anti-clotting medication is typically recommended. Anti-clotting medications include warfarin and direct oral anticoagulants. Most people are at higher risk of stroke. While these medications reduce stroke risk, they increase rates of major bleeding.Atrial fibrillation is the most common serious abnormal heart rhythm. In Europe and North America, as of 2014, it affects about 2 to 3% of the population. This is an increase from 0.4 to 1% of the population around 2005. In the developing world, about 0.6% of males and 0.4% of females are affected. The percentage of people with AF increases with age with 0.1% under 50 years old, 4% between 60 and 70 years old, and 14% over 80 years old being affected. A-fib and atrial flutter resulted in 193,300 deaths in 2015, up from 29,000 in 1990. The first known report of an irregular pulse was by Jean-Baptiste de Sénac in 1749. This was first documented by ECG in 1909 by Thomas Lewis.

Browse All Tags